AssetMark’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.48K Sell
170
-10
-6% -$541 ﹤0.01% 2526
2026
Q2
$9.9K Buy
180
+65
+57% +$2.66K ﹤0.01% 2453
2026
Q1
$3.82K Buy
115
+2
+2% +$60 ﹤0.01% 2665
2025
Q4
$3.37K Buy
113
+11
+11% +$359 ﹤0.01% 2606
2025
Q3
$3.68K Sell
102
-5
-5% -$165 ﹤0.01% 2438
2025
Q2
$3.85K Buy
107
+16
+18% +$596 ﹤0.01% 2216
2025
Q1
$3.59K Hold
91
– – ﹤0.01% 2059
2024
Q4
$2.74K Hold
91
– – ﹤0.01% 2052
2024
Q3
$2.13K Buy
+91
New +$1.99K ﹤0.01% 1878

Other funds holding TGTX

AssetMark's TGTX Position: Q3 2026 in Review

AssetMark reduced its TG Therapeutics (TGTX) stake by 5.6% in Q3 2026, selling an estimated $541 and leaving 170 shares worth $9.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

AssetMark first reported a position in TGTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $9.9K in Q2 2026. 369 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • AssetMark held 170 shares of TG Therapeutics worth $9.48K as of Q3 2026.
  • AssetMark sold 10 TG Therapeutics shares in Q3 2026, an estimated $541.
  • TG Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2526 holding.
  • AssetMark first reported a position in TG Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • AssetMark's TG Therapeutics position peaked at $9.9K in Q2 2026.
  • 369 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.